Your browser doesn't support javascript.
loading
Spatial genomic heterogeneity within localized, multifocal prostate cancer.
Boutros, Paul C; Fraser, Michael; Harding, Nicholas J; de Borja, Richard; Trudel, Dominique; Lalonde, Emilie; Meng, Alice; Hennings-Yeomans, Pablo H; McPherson, Andrew; Sabelnykova, Veronica Y; Zia, Amin; Fox, Natalie S; Livingstone, Julie; Shiah, Yu-Jia; Wang, Jianxin; Beck, Timothy A; Have, Cherry L; Chong, Taryne; Sam, Michelle; Johns, Jeremy; Timms, Lee; Buchner, Nicholas; Wong, Ada; Watson, John D; Simmons, Trent T; P'ng, Christine; Zafarana, Gaetano; Nguyen, Francis; Luo, Xuemei; Chu, Kenneth C; Prokopec, Stephenie D; Sykes, Jenna; Dal Pra, Alan; Berlin, Alejandro; Brown, Andrew; Chan-Seng-Yue, Michelle A; Yousif, Fouad; Denroche, Robert E; Chong, Lauren C; Chen, Gregory M; Jung, Esther; Fung, Clement; Starmans, Maud H W; Chen, Hanbo; Govind, Shaylan K; Hawley, James; D'Costa, Alister; Pintilie, Melania; Waggott, Daryl; Hach, Faraz.
  • Boutros PC; 1] Ontario Institute for Cancer Research, Toronto, Ontario, Canada. [2] Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada. [3] Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada.
  • Fraser M; Ontario Cancer Institute, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Harding NJ; Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
  • de Borja R; Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
  • Trudel D; Department of Pathology and Laboratory Medicine, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada.
  • Lalonde E; 1] Ontario Institute for Cancer Research, Toronto, Ontario, Canada. [2] Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.
  • Meng A; Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada.
  • Hennings-Yeomans PH; Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
  • McPherson A; School of Computing Science, Simon Fraser University, Burnaby, British Columbia, Canada.
  • Sabelnykova VY; Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
  • Zia A; Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
  • Fox NS; 1] Ontario Institute for Cancer Research, Toronto, Ontario, Canada. [2] Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.
  • Livingstone J; Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
  • Shiah YJ; Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
  • Wang J; Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
  • Beck TA; Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
  • Have CL; Department of Pathology and Laboratory Medicine, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada.
  • Chong T; Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
  • Sam M; Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
  • Johns J; Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
  • Timms L; Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
  • Buchner N; Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
  • Wong A; Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
  • Watson JD; Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
  • Simmons TT; Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
  • P'ng C; Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
  • Zafarana G; Ontario Cancer Institute, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Nguyen F; Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
  • Luo X; Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
  • Chu KC; Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
  • Prokopec SD; Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
  • Sykes J; Department of Biostatistics, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Dal Pra A; Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada.
  • Berlin A; Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada.
  • Brown A; Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
  • Chan-Seng-Yue MA; Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
  • Yousif F; Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
  • Denroche RE; Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
  • Chong LC; Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
  • Chen GM; Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
  • Jung E; Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
  • Fung C; Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
  • Starmans MH; Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
  • Chen H; Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
  • Govind SK; Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
  • Hawley J; Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
  • D'Costa A; Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
  • Pintilie M; Department of Biostatistics, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Waggott D; Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
  • Hach F; School of Computing Science, Simon Fraser University, Burnaby, British Columbia, Canada.
Nat Genet ; 47(7): 736-45, 2015 Jul.
Article en En | MEDLINE | ID: mdl-26005866
ABSTRACT
Herein we provide a detailed molecular analysis of the spatial heterogeneity of clinically localized, multifocal prostate cancer to delineate new oncogenes or tumor suppressors. We initially determined the copy number aberration (CNA) profiles of 74 patients with index tumors of Gleason score 7. Of these, 5 patients were subjected to whole-genome sequencing using DNA quantities achievable in diagnostic biopsies, with detailed spatial sampling of 23 distinct tumor regions to assess intraprostatic heterogeneity in focal genomics. Multifocal tumors are highly heterogeneous for single-nucleotide variants (SNVs), CNAs and genomic rearrangements. We identified and validated a new recurrent amplification of MYCL, which is associated with TP53 deletion and unique profiles of DNA damage and transcriptional dysregulation. Moreover, we demonstrate divergent tumor evolution in multifocal cancer and, in some cases, tumors of independent clonal origin. These data represent the first systematic relation of intraprostatic genomic heterogeneity to predicted clinical outcome and inform the development of novel biomarkers that reflect individual prognosis.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Próstata Tipo de estudio: Prognostic_studies Límite: Humans / Male / Middle aged Idioma: En Año: 2015 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Próstata Tipo de estudio: Prognostic_studies Límite: Humans / Male / Middle aged Idioma: En Año: 2015 Tipo del documento: Article